Peter J M Openshaw

List of Publications by Year
in descending order

248	24,265	8181 76	9861 141
papers	citations	h-index	g-index

340	340	340	34693
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Resilience of the respiratory microbiome in controlled adult RSV challenge study. European Respiratory Journal, 2022, 59, 2101932.	6.7	4
2	Respiratory Syncytial Virusâ€“Associated Hospital Admissions and Bed Days in Children <5 Years of Age in 7 European Countries. Journal of Infectious Diseases, 2022, 226, S22-S28.	4.0	19
3	Using correlates to accelerate vaccinology. Science, 2022, 375, 22-23.	12.6	13
4	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. Human Genetics, 2022, 141, 147-173.	3.8	22
5	Patient Involvement in RSV Research: Towards Patients Setting the Research Agenda. Journal of Infectious Diseases, 2022, 226, S130-S134.	4.0	3
6	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nature Medicine, 2022, 28, 1031-1041.	30.7	281
7	Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature, 2022, 607, 97-103.	27.8	174
8	Mucosal Immune Responses to Respiratory Syncytial Virus. Cells, 2022, 11, 1153.	4.1	13
9	SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet, The, 2022, 399, 1463-1464.	13.7	178
10	Inhaled corticosteroids: not just for asthma, but for COVID-19?. Lancet Respiratory Medicine,the, 2022, 10, 526-527.	10.7	4
11	Corticosteroid Use in Otolaryngology: Current Considerations During the COVIDâ€19 Era. Otolaryngology - Head and Neck Surgery, 2022, 167, 803-820.	1.9	8
12	Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. Thorax, 2022, 77, 606-615.	5.6	24
13	Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study. Scientific Reports, 2022, 12, 6843.	3.3	12
14	¹H NMR Signals from Urine Excreted Protein Are a Source of Bias in Probabilistic Quotient Normalization. Analytical Chemistry, 2022, 94, 6919-6923.	6.5	2
15	Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. Open Forum Infectious Diseases, 2022, 9, ofac179.	0.9	10
16	Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus. Frontiers in Immunology, 2022, 13, 807104.	4.8	6
17	Analysis of SARS-CoV-2 known and novel subgenomic mRNAs in cell culture, animal model, and clinical samples using LeTRS, a bioinformatic tool to identify unique sequence identifiers. GigaScience, 2022, 11, .	6.4	8
18	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. JCI Insight, 2022, 7, .	5.0	24

#	Article	IF	Citations
19	Controlled Human Infection Challenge Studies with RSV. Current Topics in Microbiology and Immunology, 2022, , .	1.1	2
20	Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model. The Lancet Healthy Longevity, 2022, 3, e405-e416.	4.6	9
21	Clonal hematopoiesis is not significantly associated with COVID-19 disease severity. Blood, 2022, 140, 1650-1655.	1.4	10
22	Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis. Journal of Allergy and Clinical Immunology, 2021, 147, 694-703.e12.	2.9	23
23	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. Nature Communications, 2021, 12, 1951.	12.8	54
24	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Science Immunology, 2021, 6, .	11.9	161
25	Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVIDâ€19: Analysis of the ISARIC CCPâ€UK Cohort. Obesity, 2021, 29, 1223-1230.	3.0	34
26	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 2021, 184, 1171-1187.e20.	28.9	541
27	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine,the, 2021, 9, 699-711.	10.7	122
28	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	12.8	102
29	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 349-359.	10.7	161
30	Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. Emerging Infectious Diseases, 2021, 27, 1-9.	4.3	20
31	COVID-19 pneumothorax in the UK: a prospective observational study using the ISARIC WHO clinical characterisation protocol. European Respiratory Journal, 2021, 58, 2100929.	6.7	21
32	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine,the, 2021, 9, 773-785.	10.7	78
33	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, The, 2021, 398, 223-237.	13.7	110
34	Aetiology of acute respiratory infection in preschool children requiring hospitalisation in Europeâ€"results from the PED-MERMAIDS multicentre caseâ€"control study. BMJ Open Respiratory Research, 2021, 8, e000887.	3.0	10
35	Obesity, chronic disease, age, and in-hospital mortality in patients with covid-19: analysis of ISARIC clinical characterisation protocol UK cohort. BMC Infectious Diseases, 2021, 21, 717.	2.9	19
36	Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses. Trends in Microbiology, 2021, 29, 648-662.	7.7	43

#	Article	IF	Citations
37	Innate-like Gene Expression of Lung-Resident Memory CD8⁺ T Cells during Experimental Human Influenza: A Clinical Study. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 826-841.	5.6	16
38	Offspring born to influenza A virus infected pregnant mice have increased susceptibility to viral and bacterial infections in early life. Nature Communications, 2021, 12, 4957.	12.8	25
39	Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. Nature Communications, 2021, 12, 5125.	12.8	16
40	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, The, 2021, 2, e354-e365.	7.3	216
41	Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Regional Health - Europe, The, 2021, 8, 100186.	5.6	191
42	Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. Lancet, The, 2021, 398, 1037-1038.	13.7	75
43	A Systematic Review and Meta-analysis of Animal Studies Investigating the Relationship Between Serum Antibody, T Lymphocytes, and Respiratory Syncytial Virus Disease. Journal of Infectious Diseases, 2021, , .	4.0	7
44	A prenylated dsRNA sensor protects against severe COVID-19. Science, 2021, 374, eabj3624.	12.6	124
45	Genetic mechanisms of critical illness in COVID-19. Nature, 2021, 591, 92-98.	27.8	1,014
46	Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study. BMJ Open, 2021, 11, e055435.	1.9	10
47	Global Disease Burden Estimates of Respiratory Syncytial Virusâ€“Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2020, 222, S577-S583.	4.0	231
48	The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2020, 222, S563-S569.	4.0	74
49	Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2020, 222, S570-S576.	4.0	54
50	Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet, The, 2020, 395, 42-52.	13.7	85
51	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	5.6	171
52	Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection. Science, 2020, 370, .	12.6	100
53	Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants. Journal of Infectious Diseases, 2020, 222, S666-S671.	4.0	11
54	Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU). Journal of Infectious Diseases, 2020, 222, S658-S665.	4.0	9

#	Article	IF	Citations
55	Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism. Viruses, 2020, 12, 1164.	3.3	51
56	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature Immunology, 2020, 21, 1336-1345.	14.5	1,066
57	Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ, The, 2020, 370, m3249.	6.0	478
58	Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ, The, 2020, 370, m3339.	6.0	779
59	Tracheostomy in the COVID-19 era: global and multidisciplinary guidance. Lancet Respiratory Medicine,the, 2020, 8, 717-725.	10.7	312
60	Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration. ESMO Open, 2020, 5, e000825.	4.5	6
61	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the Rheumatic Diseases, 2020, 79, 851-858.	0.9	204
62	Global outbreak research: harmony not hegemony. Lancet Infectious Diseases, The, 2020, 20, 770-772.	9.1	40
63	Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respiratory Medicine,the, 2020, 8, 822-830.	10.7	110
64	A New Role for CXCL4 in Respiratory Syncytial Virus Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 648-649.	5.6	3
65	Using imaging to combat a pandemic: rationale for developing the UK National COVID-19 Chest Imaging Database. European Respiratory Journal, 2020, 56, 2001809.	6.7	24
66	COVIDâ€19: Lessons from SARS and MERS. European Journal of Immunology, 2020, 50, 308-311.	2.9	105
67	Toward unified molecular surveillance of RSV: A proposal for genotype definition. Influenza and Other Respiratory Viruses, 2020, 14, 274-285.	3.4	52
68	A High-Fat Diet Increases Influenza A Virus-Associated Cardiovascular Damage. Journal of Infectious Diseases, 2020, 222, 820-831.	4.0	21
69	Seasonal and pandemic influenza: 100 years of progress, still much to learn. Mucosal Immunology, 2020, 13, 566-573.	6.0	50
70	Immunological and Inflammatory Biomarkers of Susceptibility and Severity in Adult Respiratory Syncytial Virus Infections. Journal of Infectious Diseases, 2020, 222, S584-S591.	4.0	10
71	Features of 20â€‰133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ, The, 2020, 369, m1985.	6.0	2,474
72	The Respiratory Mucosa: Front and Center in Respiratory Syncytial Virus Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1340-1342.	5.6	1

#	Article	IF	Citations
73	Transcriptional profiling unveils type I and II interferon networks in blood and tissues across diseases. Nature Communications, 2019, 10, 2887.	12.8	65
74	Patterns of systemic and local inflammation in patients with asthma hospitalised with influenza. European Respiratory Journal, 2019, 54, 1900949.	6.7	22
75	OMIPâ€062: A 14â€Color, 16â€Antibody Panel for Immunophenotyping Human Innate Lymphoid, Myeloid and T Cells in Small Volumes of Whole Blood and Pediatric Airway Samples. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 1231-1235.	1.5	8
76	A41â€ƒDeep sequencing of respiratory syncytial virus links viral diversity to disease severity. Virus Evolution, 2019, 5, .	4.9	0
77	Induction of innate cytokine responses by respiratory mucosal challenge with R848 in zebrafish, mice, and humans. Journal of Allergy and Clinical Immunology, 2019, 144, 342-345.e7.	2.9	8
78	Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 481-492.	5.6	30
79	Respiratory syncytial virus (RSV): a scourge from infancy to old age. Thorax, 2019, 74, 986-993.	5.6	96
80	Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection. Journal of Clinical Investigation, 2019, 130, 523-538.	8.2	42
81	Enhanced in vivo mucosal interferon and chemokine responses to a single stranded RNA analogue (R848) in participants with asthma. , 2019, , .		1
82	Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples. Journal of Visualized Experiments, 2018, , .	0.3	32
83	Biphasic activation of complement and fibrinolysis during the human nasal allergic response. Journal of Allergy and Clinical Immunology, 2018, 141, 1892-1895.e6.	2.9	8
84	Reduced Nasal Viral Load and IFN Responses in Infants with Respiratory Syncytial Virus Bronchiolitis and Respiratory Failure. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1074-1084.	5.6	73
85	Vaccination policies in Europe: Common goals, diverse approaches and public doubts. European Journal of Immunology, 2018, 48, 10-12.	2.9	6
86	Influenza burden, prevention, and treatment in asthmaâ€A scoping review by the <scp>EAACI</scp> Influenza in asthma task force. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1151-1181.	5.7	47
87	Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. Journal of Virology, 2018, 92, .	3.4	55
88	Men and Women in Immunology: Closing the gap on gender parity?. European Journal of Immunology, 2018, 48, 1776-1779.	2.9	2
89	Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza. Nature Immunology, 2018, 19, 625-635.	14.5	119
90	The 1918 Influenza Pandemic: one hundred years of progress, but where now?. Lancet Respiratory Medicine,the, 2018, 6, 588-589.	10.7	8

#	Article	IF	Citations
91	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infectious Diseases, The, 2018, 18, e295-e311.	9.1	355
92	The role of innate lymphoid cells in early life lung infection. , 2018, , .		0
93	RSV Takes Control of Neonatal Breg Cells: Two Hands on the Wheel. Immunity, 2017, 46, 171-173.	14.3	4
94	Protective and Harmful Immunity to RSV Infection. Annual Review of Immunology, 2017, 35, 501-532.	21.8	169
95	Maternal immunisation: collaborating with mother nature. Lancet Infectious Diseases, The, 2017, 17, e197-e208.	9.1	133
96	Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. Lancet Infectious Diseases, The, 2017, 17, e223-e234.	9.1	73
97	Activation of the Complement, Coagulation and Fibrinolysis Pathways after Nasal Allergen Challenge. Journal of Allergy and Clinical Immunology, 2017, 139, AB384.	2.9	0
98	Nasosorption as a Minimally Invasive Sampling Procedure: Mucosal Viral Load and Inflammation in Primary RSV Bronchiolitis. Journal of Infectious Diseases, 2017, 215, 1240-1244.	4.0	29
99	Vaccines in the Prevention of Viral Pneumonia. Clinics in Chest Medicine, 2017, 38, 155-169.	2.1	8
100	Issues in vaccinology: Present challenges and future directions. European Journal of Immunology, 2017, 47, 2017-2025.	2.9	24
101	Viva Europa, a Land of Excellence in Research and Innovation for Health and Wellbeing. Progress in Preventive Medicine (New York, N Y), 2017, 2, e006.	0.7	6
102	S68â€…Phase 1 trial of an intranasal respiratory syncytial virus (rsv) subunit candidate vaccine: safety results from the muc-syngem study. , 2017, , .		0
103	M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. JCI Insight, 2017, 2, e91868.	5.0	59
104	The Effect of Vitamin D Supplementation on Mucosal IL-5, MMP9 and Cathelicidin after Nasal Allergen Challenge with Grass Pollen. Journal of Allergy and Clinical Immunology, 2016, 137, AB73.	2.9	1
105	The Helminth-Derived Immunomodulator AvCystatin Reduces Virus Enhanced Inflammation by Induction of Regulatory IL-10+ T Cells. PLoS ONE, 2016, 11, e0161885.	2.5	17
106	LSC Abstract â€“ The AsthmaMap: Towards a community-driven reconstruction of asthma-relevant pathways and networks. , 2016, , .		1
107	Asthma patients hospitalized with influenza lack mucosal and systemic type 2 inflammation. , 2016, , .		0
108	RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. Nature Communications, 2015, 6, 10224.	12.8	237

#	Article	IF	Citations
109	How should influenza be treated? Focus on antivirals. Vaccine, 2015, 33, 7033-7036.	3.8	0
110	Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1040-1049.	5.6	216
111	Effect of ethnicity on care pathway and outcomes in patients hospitalized with influenza A(H1N1)pdm09 in the UK. Epidemiology and Infection, 2015, 143, 1129-1138.	2.1	11
112	Antiviral B cell and T cell immunity in the lungs. Nature Immunology, 2015, 16, 18-26.	14.5	115
113	Nasal Lipopolysaccharide Challenge and Cytokine Measurement Reflects Innate Mucosal Immune Responsiveness. PLoS ONE, 2015, 10, e0135363.	2.5	19
114	Attenuated Bordetella pertussis Vaccine Protects against Respiratory Syncytial Virus Disease via an IL-17â€“Dependent Mechanism. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 194-202.	5.6	38
115	Live Attenuated B. pertussis BPZE1 Rescues the Immune Functions of Respiratory Syncytial Virus Infected Human Dendritic Cells by Promoting Th1/Th17 Responses. PLoS ONE, 2014, 9, e100166.	2.5	12
116	Delayed Sequelae of Neonatal Respiratory Syncytial Virus Infection Are Dependent on Cells of the Innate Immune System. Journal of Virology, 2014, 88, 604-611.	3.4	43
117	Immunity to RSV in Early-Life. Frontiers in Immunology, 2014, 5, 466.	4.8	154
118	Open source clinical science for emerging infections. Lancet Infectious Diseases, The, 2014, 14, 8-9.	9.1	82
119	Current concepts and progress in RSV vaccine development. Expert Review of Vaccines, 2014, 13, 333-344.	4.4	44
120	Alpha/Beta Interferon Receptor Signaling Amplifies Early Proinflammatory Cytokine Production in the Lung during Respiratory Syncytial Virus Infection. Journal of Virology, 2014, 88, 6128-6136.	3.4	122
121	Accumulation of Human-Adapting Mutations during Circulation of A(H1N1)pdm09 Influenza Virus in Humans in the United Kingdom. Journal of Virology, 2014, 88, 13269-13283.	3.4	84
122	Neuraminidase inhibitors for influenza complicationsâ€“Authors' reply. Lancet, The, 2014, 384, 1261-1262.	13.7	1
123	Antivirals for influenza: where now for clinical practice and pandemic preparedness?. Lancet, The, 2014, 384, 386-387.	13.7	11
124	Natural killer cell NKG2D and granzyme B are critical forÂallergic pulmonary inflammationâ€†. Journal of Allergy and Clinical Immunology, 2014, 133, 827-835.e3.	2.9	43
125	Protective and dysregulated T cell immunity in RSV infection. Current Opinion in Virology, 2013, 3, 468-474.	5.4	91
126	Microbes and mucosal immune responses in asthma. Lancet, The, 2013, 381, 861-873.	13.7	134

#	Article	IF	Citations
127	Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. European Respiratory Journal, 2013, 41, 824-831.	6.7	46
128	Regulatory T Cells Prevent Th2 Immune Responses and Pulmonary Eosinophilia during Respiratory Syncytial Virus Infection in Mice. Journal of Virology, 2013, 87, 10946-10954.	3.4	84
129	Endogenous IL-21 regulates pathogenic mucosal CD4 T-cell responses during enhanced RSV disease in mice. Mucosal Immunology, 2013, 6, 704-717.	6.0	11
130	A Gene Expression Signature for RSV: Clinical Implications and Limitations. PLoS Medicine, 2013, 10, e1001550.	8.4	5
131	Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2987-2992.	7.1	90
132	Neonatal antibody responses are attenuated by interferon-Î³ produced by NK and T cells during RSV infection. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5576-5581.	7.1	36
133	The Mouse Model of Respiratory Syncytial Virus Disease. Current Topics in Microbiology and Immunology, 2013, 372, 359-369.	1.1	20
134	An Evaluation of Community Assessment Tools (CATs) in Predicting Use of Clinical Interventions and Severe Outcomes during the A(H1N1)pdm09 Pandemic. PLoS ONE, 2013, 8, e75384.	2.5	5
135	Benefit and harm from immunity to respiratory syncytial virus. Current Opinion in Infectious Diseases, 2012, 25, 687-694.	3.1	19
136	Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunology, 2012, 5, 161-172.	6.0	156
137	OX40 Ligand and Programmed Cell Death 1 Ligand 2 Expression on Inflammatory Dendritic Cells Regulates CD4 T Cell Cytokine Production in the Lung during Viral Disease. Journal of Immunology, 2012, 188, 1647-1655.	0.8	14
138	IFITM3 restricts the morbidity and mortality associated with influenza. Nature, 2012, 484, 519-523.	27.8	668
139	Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009â€“2010 in the UK. Thorax, 2012, 67, 709-717.	5.6	76
140	IFITM3 restricts the morbidity and mortality associated with influenza. International Journal of Infectious Diseases, 2012, 16, e79.	3.3	5
141	Preexposure to CpG Protects against the Delayed Effects of Neonatal Respiratory Syncytial Virus Infection. Journal of Virology, 2012, 86, 10456-10461.	3.4	28
142	Predominance of heterosubtypic <scp>IFN</scp>â€Î³â€onlyâ€secreting effector memory <scp>T</scp> cells in pandemic <scp>H</scp>1<scp>N</scp>1 naive adults. European Journal of Immunology, 2012, 42, 2913-2924.	2.9	34
143	Human microbial challenge: the ultimate animal model. Lancet Infectious Diseases, The, 2012, 12, 903-905.	9.1	36
144	Comparison of CATs, CURB-65 and PMEWS as Triage Tools in Pandemic Influenza Admissions to UK Hospitals: Case Control Analysis Using Retrospective Data. PLoS ONE, 2012, 7, e34428.	2.5	14

#	Article	IF	Citations
145	The microbiology of asthma. Nature Reviews Microbiology, 2012, 10, 459-471.	28.6	170
146	IL-10 Regulates Viral Lung Immunopathology during Acute Respiratory Syncytial Virus Infection in Mice. PLoS ONE, 2012, 7, e32371.	2.5	116
147	The Comparative Clinical Course of Pregnant and Non-Pregnant Women Hospitalised with Influenza A(H1N1)pdm09 Infection. PLoS ONE, 2012, 7, e41638.	2.5	14
148	Severe Influenza: Clinical Features and Treatment Options. Current Respiratory Medicine Reviews, 2012, 8, 208-227.	0.2	3
149	Contribution of cytokines to pathology and protection in virus infection. Current Opinion in Virology, 2011, 1, 184-195.	5.4	24
150	Doctors accepting flu vaccination is the sensible and responsible choice. BMJ: British Medical Journal, 2011, 343, d7199-d7199.	2.3	0
151	Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. European Respiratory Journal, 2011, 38, 401-408.	6.7	52
152	Nosocomial Pandemic (H1N1) 2009, United Kingdom, 2009â€“2010. Emerging Infectious Diseases, 2011, 17, 592-598.	4.3	53
153	RSV-Induced Bronchial Epithelial Cell PD-L1 Expression Inhibits CD8+ T Cell Nonspecific Antiviral Activity. Journal of Infectious Diseases, 2011, 203, 85-94.	4.0	66
154	Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adults. Thorax, 2011, 66, 247-252.	5.6	30
155	Pre-Admission Statin Use and In-Hospital Severity of 2009 Pandemic Influenza A(H1N1) Disease. PLoS ONE, 2011, 6, e18120.	2.5	49
156	Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. Blood, 2010, 115, 396-407.	1.4	47
157	Delivery of Cytokines by Recombinant Virus in Early Life Alters the Immune Response to Adult Lung Infection. Journal of Virology, 2010, 84, 5294-5302.	3.4	28
158	CD25 ⁺ Natural Regulatory T Cells Are Critical in Limiting Innate and Adaptive Immunity and Resolving Disease following Respiratory Syncytial Virus Infection. Journal of Virology, 2010, 84, 8790-8798.	3.4	133
159	Impact of the 2009 influenza pandemic. Thorax, 2010, 65, 471-472.	5.6	11
160	Genetic Susceptibility to the Delayed Sequelae of Neonatal Respiratory Syncytial Virus Infection Is MHC Dependent. Journal of Immunology, 2010, 185, 5384-5391.	0.8	36
161	Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax, 2010, 65, 645-651.	5.6	214
162	Interleukin 18 Coexpression during Respiratory Syncytial Virus Infection Results in Enhanced Disease Mediated by Natural Killer Cells. Journal of Virology, 2010, 84, 4073-4082.	3.4	50

#	Article	IF	Citations
163	Influenza vaccination: lessons learned from the pandemic (H1N1) 2009 influenza outbreak. Mucosal Immunology, 2010, 3, 422-424.	6.0	9
164	The Chemokine MIP1Î±/CCL3 Determines Pathology in Primary RSV Infection by Regulating the Balance of T Cell Populations in the Murine Lung. PLoS ONE, 2010, 5, e9381.	2.5	51
165	Pulmonary VÎ³4+Î³Î´ T Cells Have Proinflammatory and Antiviral Effects in Viral Lung Disease. Journal of Immunology, 2009, 182, 1174-1181.	0.8	63
166	Emerging drugs for respiratory syncytial virus infection. Expert Opinion on Emerging Drugs, 2009, 14, 207-217.	2.4	48
167	Crossing barriers: infections of the lung and the gut. Mucosal Immunology, 2009, 2, 100-102.	6.0	45
168	IL-9 Regulates Pathology during Primary and Memory Responses to Respiratory Syncytial Virus Infection. Journal of Immunology, 2009, 183, 7006-7013.	0.8	41
169	Respiratory syncytial virus infection provokes airway remodelling in allergenâ€exposed mice in absence of prior allergen sensitization. Clinical and Experimental Allergy, 2008, 38, 1016-1024.	2.9	51
170	CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clinical and Experimental Immunology, 2008, 88, 527-536.	2.6	147
171	Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination. Vaccine, 2008, 26, 753-761.	3.8	19
172	Alveolar Macrophages Are a Major Determinant of Early Responses to Viral Lung Infection but Do Not Influence Subsequent Disease Development. Journal of Virology, 2008, 82, 4441-4448.	3.4	185
173	The Role of T Cells in the Enhancement of Respiratory Syncytial Virus Infection Severity during Adult Reinfection of Neonatally Sensitized Mice. Journal of Virology, 2008, 82, 4115-4124.	3.4	107
174	Susan Elizabeth Openshaw (nÃ©e Scott Stokes). BMJ: British Medical Journal, 2008, 336, 621.6-621.	2.3	0
175	Virally Delivered Cytokines Alter the Immune Response to Future Lung Infections. Journal of Virology, 2007, 81, 13105-13111.	3.4	28
176	Functional Characterisation of Alloreactive T-Cells Identifies CD25 and CD71 as the Optimal Targets for Allodepletion Strategies.. Blood, 2007, 110, 2183-2183.	1.4	0
177	Bronchiolitis. Lancet, The, 2006, 368, 312-322.	13.7	381
178	T cells take the inside track. Nature Medicine, 2006, 12, 614-615.	30.7	1
179	A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nature Medicine, 2006, 12, 905-907.	30.7	187
180	Respiratory Syncytial Virus, Airway Inflammation, and FEV₁ Decline in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 871-876.	5.6	169

#	Article	IF	Citations
181	Role of CCL5 (RANTES) in Viral Lung Disease. Journal of Virology, 2006, 80, 8151-8157.	3.4	106
182	Differential Chemokine Expression following Respiratory Virus Infection Reflects Th1- or Th2-Biased Immunopathology. Journal of Virology, 2006, 80, 4521-4527.	3.4	98
183	Immune tolerance to hepatitis C virus acquired during engraftment of bone marrow transplant. Journal of Viral Hepatitis, 2005, 12, 604-608.	2.0	3
184	Role of CCL11 in Eosinophilic Lung Disease during Respiratory Syncytial Virus Infection. Journal of Virology, 2005, 79, 2050-2057.	3.4	53
185	Antiviral Immune Responses and Lung Inflammation after Respiratory Syncytial Virus Infection. Proceedings of the American Thoracic Society, 2005, 2, 121-125.	3.5	43
186	The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Respiratory Research, 2005, 6, 70.	3.6	51
187	Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection. Clinical Microbiology Reviews, 2005, 18, 541-555.	13.6	263
188	Vaccines for the prevention of respiratory viral infections: problems and current status. Expert Opinion on Investigational Drugs, 2004, 13, 681-689.	4.1	2
189	Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis. Journal of General Virology, 2004, 85, 3017-3026.	2.9	19
190	What does the peripheral blood tell you in SARS?. Clinical and Experimental Immunology, 2004, 136, 11-12.	2.6	22
191	Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection. Microbes and Infection, 2004, 6, 666-675.	1.9	12
192	Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes and Infection, 2004, 6, 1049-1055.	1.9	30
193	Childhood infections, the developing immune system, and the origins of asthma. Journal of Allergy and Clinical Immunology, 2004, 114, 1275-1277.	2.9	45
194	Latency and Persistence of Respiratory Syncytial Virus Despite T Cell Immunity. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 801-805.	5.6	143
195	Respiratory syncytial virus and other pneumoviruses: a review of the international symposiumâ€"RSV 2003. Virus Research, 2004, 106, 1-13.	2.2	21
196	Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine, 2004, 23, 215-221.	3.8	37
197	RSV bronchiolitis, Î³Î´ T cells and asthma: are they linked?. Clinical and Experimental Immunology, 2003, 131, 197-198.	2.6	6
198	Where is SARS now?. Thorax, 2003, 58, 650-651.	5.6	1

#	Article	IF	Citations
199	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, S58-S65.	2.0	21
200	Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatric Infectious Disease Journal, 2003, 22, S58-S65.	2.0	107
201	Prior Exposure to Live Mycobacterium bovis BCG Decreases Cryptococcus neoformans -Induced Lung Eosinophilia in a Gamma Interferon-Dependent Manner. Infection and Immunity, 2003, 71, 3384-3391.	2.2	24
202	Animal Models of Viral Respiratory Infections. , 2003, , .		0
203	Development of vaccines against common colds. British Medical Bulletin, 2002, 62, 99-111.	6.9	15
204	Evolution of Epitope-Specific Memory CD4+ T Cells After Clearance of Hepatitis C Virus. Journal of Immunology, 2002, 169, 2210-2214.	0.8	99
205	Pulmonary defences to acute respiratory infection. British Medical Bulletin, 2002, 61, 1-12.	6.9	81
206	Age at First Viral Infection Determines the Pattern of T Cellâ€“mediated Disease during Reinfection in Adulthood. Journal of Experimental Medicine, 2002, 196, 1381-1386.	8.5	237
207	Enhanced ILâ€4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy. European Respiratory Journal, 2002, 20, 376-382.	6.7	71
208	Potential therapeutic implications of new insights into respiratory syncytial virus disease. Respiratory Research, 2002, 3, S15-20.	3.6	31
209	Current research on respiratory viral infections: Fourth International Symposium. Antiviral Research, 2002, 55, 227-278.	4.1	43
210	Increased aeroallergenâ€specific interleukinâ€4â€producing T cells in asthmatic adults. Clinical and Experimental Allergy, 2002, 32, 1739-1744.	2.9	15
211	Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine, 2001, 20, S27-S31.	3.8	140
212	The protective effect of childhood infections. BMJ: British Medical Journal, 2001, 322, 376-377.	2.3	29
213	Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. European Journal of Immunology, 2001, 31, 1438-1446.	2.9	60
214	Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. European Journal of Immunology, 2001, 31, 2566-2573.	2.9	274
215	Long-term persistence and reactivation of T cell memory in the lung of mice infected with respiratory syncytial virus. European Journal of Immunology, 2001, 31, 2574-2582.	2.9	84
216	An improved protocol for measuring cytotoxic T cell activity in anatomic compartments with low cell numbers. Journal of Immunological Methods, 2001, 257, 155-161.	1.4	17

#	Article	IF	Citations
217	Inhibition of T1/St2 during Respiratory Syncytial Virus Infection Prevents T Helper Cell Type 2 (Th2)- but Not Th1-Driven Immunopathology. Journal of Experimental Medicine, 2001, 193, 785-792.	8.5	104
218	Mucosal Delivery of a Respiratory Syncytial Virus CTL Peptide with Enterotoxin-Based Adjuvants Elicits Protective, Immunopathogenic, and Immunoregulatory Antiviral CD8+ T Cell Responses. Journal of Immunology, 2001, 166, 1106-1113.	0.8	94
219	Potential Mechanisms Causing Delayed Effects of Respiratory Syncytial Virus Infection. American Journal of Respiratory and Critical Care Medicine, 2001, 163, S10-S13.	5.6	24
220	Partners in crime: co-infections in the developing world. Clinical and Experimental Immunology, 2000, 122, 296-299.	2.6	9
221	Reply to Rook. Trends in Immunology, 2000, 21, 249-250.	7.5	16
222	Flow cytometric measurement of intracellular cytokines. Journal of Immunological Methods, 2000, 243, 107-124.	1.4	203
223	IL-12-Activated NK Cells Reduce Lung Eosinophilia to the Attachment Protein of Respiratory Syncytial Virus But Do Not Enhance the Severity of Illness in CD8 T Cell-Immunodeficient Conditions. Journal of Immunology, 2000, 165, 7109-7115.	0.8	68
224	Influenza Virus Lung Infection Protects from Respiratory Syncytial Virusâ€“Induced Immunopathology. Journal of Experimental Medicine, 2000, 192, 1317-1326.	8.5	127
225	Infections prevent the development of asthmaâ€”true, false or both?. Journal of the Royal Society of Medicine, 1999, 92, 495-499.	2.0	13
226	Recent developments in the biology of respiratory syncytial virus: are vaccines and new treatments just round the corner?. Current Opinion in Microbiology, 1999, 2, 410-414.	5.1	15
227	Respiratory syncytial virus and wheeze. Lancet, The, 1999, 354, 1997-1998.	13.7	22
228	Anaphylactic sensitization to aeroantigen during respiratory virus infection. Clinical and Experimental Allergy, 1998, 28, 1501-1508.	2.9	65
229	Respiratory syncytial virus RNA in cells from the peripheral blood during acute infection. Journal of Pediatrics, 1998, 133, 272-274.	1.8	57
230	Eliminating a Region of Respiratory Syncytial Virus Attachment Protein Allows Induction of Protective Immunity without Vaccine-enhanced Lung Eosinophilia. Journal of Experimental Medicine, 1998, 187, 1921-1926.	8.5	137
231	CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. European Journal of Immunology, 1997, 27, 3341-3349.	2.9	222
232	Mouse Î³Î´TCR+NK1.1+ thymocytes specifically produce interleukin-4, are major histocompatibility complex class I independent, and are developmentally related to Î±Î² TCR+NK1.1+ thymocytes. European Journal of Immunology, 1996, 26, 1424-1429.	2.9	63
233	Reversibility of T helper 1 and 2 populations is lost after long-term stimulation.. Journal of Experimental Medicine, 1996, 183, 901-913.	8.5	401
234	Beneficial and Harmful Immune Responses in the Respiratory Tract. , 1996, , 449-457.		2

#	Article	IF	Citations
235	Immunopathological mechanisms in respiratory syncytial virus disease. Seminars in Immunopathology, 1995, 17, 187-201.	4.0	89
236	Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations.. Journal of Experimental Medicine, 1995, 182, 1357-1367.	8.5	547
237	Immunity and Immunopathology to Respiratory Syncytial Virus. American Journal of Respiratory and Critical Care Medicine, 1995, 152, S59-S62.	5.6	143
238	Distinct types of lung disease caused by functional subsets of antiviral T cells.. Journal of Experimental Medicine, 1994, 179, 81-89.	8.5	318
239	Response from Openshaw. Trends in Microbiology, 1994, 2, 149-150.	7.7	1
240	Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. Vaccine, 1993, 11, 431-437.	3.8	86
241	Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. International Immunology, 1992, 4, 493-500.	4.0	220
242	Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. Journal of Virology, 1992, 66, 2102-2110.	3.4	128
243	The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. Journal of Virology, 1990, 64, 1683-1689.	3.4	110
244	MHC and antigen presentation. Trends in Immunology, 1989, 10, 396-397.	7.5	3
245	Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus.. Journal of Experimental Medicine, 1988, 168, 1163-1168.	8.5	454
246	Changes in rib cage geometry during childhood.. Thorax, 1984, 39, 624-627.	5.6	117
247	COVID-19 and beyond:Âa call for action andÂaudacious solidarity to all the citizens and nations,Âit is humanityâ€™s fight. F1000Research, 0, 9, 1130.	1.6	3
248	Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients. SSRN Electronic Journal, 0, , .	0.4	56